Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
- 14 July 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 71 (14), 4821-4833
- https://doi.org/10.1158/0008-5472.can-11-0950
Abstract
Immunogenic cell death is characterized by the early surface exposure of chaperones including calreticulin and HSPs, which affect dendritic cell (DC) maturation and the uptake and presentation of tumor antigens. It has also been shown that it is characterized by the late release of high mobility group box 1 (HMGB1), which acts through Toll-like receptor 4 (TLR4) and augments the presentation of antigens from dying tumor cells to DCs. Most of the data on immunogenic tumor cell death were obtained using mouse models. In this study, we investigated the capacity of clinically used chemotherapeutics to induce immunogenic cell death in human tumor cell lines and primary tumor cells. We found that only anthracyclines induced a rapid translocation of calreticulin, HSP70, and HSP90 to the cell surface and the release of HMGB1 12 hours after the treatment. The interaction of immature DCs with immunogenic tumor cells led to an increased tumor cell uptake and induces moderate phenotypic maturation of DCs. Killed tumor cell–loaded DCs efficiently stimulated tumor-specific IFN-γ–producing T cells. DCs pulsed with killed immunogenic tumor cells also induced significantly lower numbers of regulatory T cells than those pulsed with nonimmunogenic tumor cells. These data indicate that human prostate cancer, ovarian cancer, and acute lymphoblastic leukemia cells share the key features of immunogenic cell death with mice tumor cells. These data also identify anthracyclines as anticancer drugs capable of inducing immunogenic cell death in sensitive human tumor cells. Cancer Res; 71(14); 4821–33. ©2011 AACR.Keywords
This publication has 28 references indexed in Scilit:
- Surface‐exposed calreticulin in the interaction between dying cells and phagocytesAnnals of the New York Academy of Sciences, 2010
- Molecular characteristics of immunogenic cancer cell deathCell Death & Differentiation, 2007
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- Towards a Better Way to Die with Chemotherapy: Role of Heat Shock Protein Exposure on Dying Tumor CellsCell Cycle, 2007
- Bortezomib enhances dendritic cell (DC)–mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implicationsBlood, 2007
- Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patientsBlood, 2006
- Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptorsClinical Immunology, 2006
- Cancer despite immunosurveillance: immunoselection and immunosubversionNature Reviews Immunology, 2006
- Caspase-dependent immunogenicity of doxorubicin-induced tumor cell deathThe Journal of Experimental Medicine, 2005
- Polyomavirus EGFP‐pseudocapsids: Analysis of model particles for introduction of proteins and peptides into mammalian cellsFEBS Letters, 2005